Cleared Traditional

K980312 - NOVA LITE ENDOMYSIAL

K980312 is the FDA 510(k) clearance for NOVA LITE ENDOMYSIAL by Inova Diagnostics, Inc.. It is a Class 2 Immunology device (product code DBL) cleared through the Traditional 510(k) pathway after a 65-day FDA review.

K980312 · Inova Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1998
Decision
65d
Days
Class 2
Risk

K980312 is an FDA 510(k) clearance for the NOVA LITE ENDOMYSIAL. Classified as Multiple Autoantibodies, Indirect Immunofluorescent, Antigen, Control (product code DBL), Class II - Special Controls.

Submitted by Inova Diagnostics, Inc. (San Diego, US). The FDA issued a Cleared decision on April 2, 1998 after a review of 65 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5660 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Inova Diagnostics, Inc. devices

Submission Details

510(k) Number K980312 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 27, 1998
Decision Date April 02, 1998
Days to Decision 65 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
39d faster than avg
Panel avg: 104d · This submission: 65d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DBL Multiple Autoantibodies, Indirect Immunofluorescent, Antigen, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5660
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DBL Multiple Autoantibodies, Indirect Immunofluorescent, Antigen, Control

All 11
Devices cleared under the same product code (DBL) and FDA review panel - the closest regulatory comparables to K980312.
Histofluor Rodent LKS Fluorescent Antibody Test System, Image Navigator by Immuno Concepts
K180202 · Immuno Concepts, N.A. , Ltd. · Oct 2018
RIT LIVER, KIDNEY, STOMACH IFA KIT
K955431 · The Binding Site, Ltd. · Apr 1996
ANTI-RETICULIN ANTIBODY (ARA) TEST
K913360 · Immco Diagnostics, Inc. · Sep 1994
ANTI-ENDOMYSIAL ANTIBODY TEST
K912551 · Immco Diagnostics, Inc. · Jun 1993
MEDICA IIF ANTI-SKIN ANTIBODY TEST KIT
K902237 · Medica Corp. · Jul 1990
ANTI-SKIN ANTIBODY TEST(MONKEY ESOPHAGUS SECTIONS)
K891098 · Immco Diagnostics, Inc. · Mar 1989